Claudia Ruiz
Psychiatric/Mental Health · Las Cruces, NMNPI 1316975675
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$514
- Teva Pharmaceuticals USA, Inc.$478
- Neurocrine Biosciences, Inc.$423
- Johnson & Johnson$415
- Axsome Therapeutics, Inc.$371
- AbbVie$363
- plus $950 from 11 others
What the payments were for
- Food & beverage$3,514100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 38 | $514 |
| Teva Pharmaceuticals USA, Inc. | 27 | $478 |
| Neurocrine Biosciences, Inc. | 21 | $423 |
| Johnson & Johnson | 22 | $415 |
| Axsome Therapeutics, Inc. | 16 | $371 |
| AbbVie | 19 | $363 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $282 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $209 |
| Otsuka America Pharmaceutical, Inc. | 6 | $135 |
| Lundbeck LLC | 6 | $109 |
| Corium, LLC | 4 | $85 |
| Vanda Pharmaceuticals Inc. | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Eisai Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Merck | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
How this compares
$3,514 in reported general payments places this provider in the 90th percentile of 228 psychiatric/mental health providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $108,661 |
| AristadaAripiprazole Lauroxil | 34 | $102,301 |
| VraylarCariprazine Hcl | 54 | $81,643 |
| RexultiBrexpiprazole | 41 | $81,493 |
| NuedextaDextromethorphan Hbr/Quinidine | 32 | $53,613 |
| Invega SustennaPaliperidone Palmitate | 15 | $48,909 |
| CaplytaLumateperone Tosylate | 12 | $22,097 |
| Lurasidone Hcl | 59 | $17,525 |
| TrintellixVortioxetine Hydrobromide | 23 | $16,809 |
| Bupropion XlBupropion Hcl | 130 | $6,371 |
| Divalproex Sodium ErDivalproex Sodium | 40 | $5,116 |
| Asenapine Maleate | 14 | $4,687 |
| Olanzapine | 101 | $3,674 |
| Aripiprazole | 112 | $3,385 |
| Buspirone Hcl | 157 | $3,356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $423 | $108,66112 claims |
| Alkermes, Inc.Aristada | $514 | $102,30134 claims |
| AbbVieVraylar | $363 | $81,64354 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $135 | $81,49341 claims |
| Johnson & JohnsonInvega Sustenna | $415 | $48,90915 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $209 | $22,09712 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $282 | $16,80923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 228 psychiatric/mental health providers in New Mexico.
Other psychiatric/mental health in Las Cruces
- Jacqueline TutonLas Cruces$10K
- Mario HerreraLas Cruces$7K
- Heidi PattarozziLas Cruces$6K
- Lorena GarciaLas Cruces$6K
- Jacquelyn WilliamsLas Cruces$4K
- Selene MendozaLas Cruces$4K
- Fernando GuillenLas Cruces$4K
- Karen LeeLas Cruces$3K
- Deanna Joy MynattLas Cruces$3K
- Maria MendozaLas Cruces$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.